Bumetanide Effect on SCI pain relief

Studying safety and efficacy of Bumetanide on relief of pharmacological treatment-resistant pain in spinal cord injury patients refered to pain clinic of Brain And Spinal Cord Injury Research Center, Emam Khomeini Hospital, Tehran, during years 1392 through 1393

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201407155368N2

Enrollment

Registered

2014-08-19

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain in spinal cord injury. Injury of spinal cord, level unspecified

Interventions

Administrating oral 1 mg bumetanide tablets, BID, for 4 months..

Treatment - Drugs

Administrating oral 1 mg bumetanide tablets, BID, for 4 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: All the patients with spinal cord injury and refractory at- or below-level pain due to the injury who signed the informed consent. Exclusion Criteria: History of renal failure; Creatinine more than 1.5 mg/dl or its increase at least 0.5 mg/dl during study; Cardiovascular diseases including heart failure, conductive disorders and MI; Hypokalemia during study; During Breast feeding; History of hypersensitivity to sulfonamides, sulfunilurea, carbonic anhydrase inhibitors and thiazides; Using cross-reacting medications like Heart Glycosides, Cisplatin, Glucocorticoids, Cyclosporine, ACE Inhibitors, Aminoglycosides, Beta2 Agonists, Allopurinol, Dofetilide, Probenecid, Risperidone, Sodium Phosphates and Topiramate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: Time0, Month4, Month8. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hadjighassem

Brain and Spinal Cord Injury Research Center

mhaji63@yahoo.com+98 21 6643 8635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026